Hansoh Pharmaceutical (03692.HK) Surges Over 6% as H1 Net Profit More Than Doubles and Innovative Product Revenue Jumps 80%

According to the Zhicheng Finance APP, Hansoh Pharma (03692) rose over 6%. As of press time, it surged 6.37%, trading at HK$19.38, with a turnover of HK$30.9019 million.

On the news front, Hansoh Pharma announced its financial results for the six months ended June 30, 2024, with revenue reaching RMB 6.506 billion (RMB, same below), representing a year-on-year increase of 44.21%; profit attributable to owners of the parent company amounted to RMB 2.726 billion, marking a year-on-year increase of 111.47%; basic earnings per share were RMB 0.46; an interim dividend of HKD 0.201 per share is proposed, compared to HKD 0.0707 per share in the same period last year.

The announcement stated that the increase in revenue, profit, and basic earnings per share during the period was mainly due to the rise in revenue from innovative drugs and collaborative products, attributed to the increase in innovative drug sales and upfront payments from partner GSK. In the first half of this year, the company's revenue from innovative drugs and collaborative products reached 5.032 billion yuan, increasing by 80.6%, and accounting for total revenue rose from 61.8% in the same period last year to 77.4%.